Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 799 results for "Ibrutinib"

Imbruvica gains breakthrough status for treating chronic lymphocytic leukemia
Examiner.com

Imbruvica gains breakthrough status for treating chronic lymph...

The FDA has expanded the use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), and thus have shown poor responses to standard treatment for the disease. The news ... Examiner.com, 4 weeks ago
FDA Expands Use of Imbruvica for Form of Leukemia US News & World Report, 1 month ago
[x]  

6 images for Ibrutinib

SearchBug, 1 month ago
Drug Discovery and Development, 1 month ago
Ecancer Medicalscience, 4 weeks ago
Examiner.com, 4 weeks ago
OncLive, 1 month ago
Scottrade, 1 month ago
Med India

A Solution to Ibrutinib Resistance in MCL?

 American Journal of Public Health3 weeks ago Erratum: Ibrutinib Resistance in Chronic Lymphocytic Leukemia  New England Journal of Medicine2 months ago Ohio State University Wexner Medical Center: Mechanisms of ibrutinib resistance identified in chronic lymphocytic leukemia  NewsRX2 months ago Mechanisms of Ibrutinib Resistance Identified in the Treatment of Chronic Lymphocytic Leukemia  Med India2 months ago

Ibrutinib in CLL: Indication Expanded, Benefit Confirmed

Ibrutinib ( Imbruvica , Pharmacyclics), hailed as a " turning point " in the treatment for chronic lymphocytic leukemia (CLL), has just had another indication and a label change approved by the US Food and Drug Administration (FDA). Ibrutinib was ...
 Medscape1 month ago Ibrutinib, Star in CLL, Subject to Lowly Drug Resistance  General Medicine eJournal2 months ago

Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval

The EU approval of Pharmacyclics ( PCYC ) and partner Johnson & Johnson's ( JNJ ) oncology drug Imbruvica (ibrutinib) appears well on track with the European Medicines Agency's ( EMA.TO ) Committee for Medicinal Products for Human Use ( CHMP ) ...
 Yahoo! Finance1 month ago FDA expands approval for Johnson & Johnson, Pharmacyclics' Imbruvica in CLL  FirstWord Pharma1 month ago
[x]  

EMA recomienda la aprobación de IMBRUVICA para el tratamiento de dos cánceres sanguíneos

-- La Agencia Europea del Medicamento(EMA) emite una opinión positiva, recomendando la aprobación de IMBRUVICA (ibrutinib) para el tratamiento de dos cánceres sanguíneos SUNNYVALE, California , 26 de julio de 2014 /PRNewswire/ ...
 PR Newswire1 month ago
Pharmaceutical Business Review

Pending EC decision: Imbruvica, Ibrutinib, Opinion date: 24-Jul-2014

the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Imbruvica 140 mg hard capsule intended for the treatment of relapsed or refractory ...
 European Medicines Agency1 month ago European Medicines Agency recommends approval of two new treatment options for rare cancers  Bionity.com3 weeks ago CHMP recommends Pharmacyclics Imbruvica to treat two blood cancers  Pharmaceutical Technology1 month ago EMA's CHMP backs approval of two new treatment options for rare cancers26-07-2014  Pharma Letter1 month ago
[x]  

Ibrutinib and Idelalisib Coming to Europe Soon

Two novel targeted agents that look to change the whole paradigm of treatment for chronic lymphocytic leukemia (CLL) look like they will be available in Europe soon. Ibrutinib ( Imbruvica , Janssen) and idelalisib ( Zydelig , Gilead) have both ...
 Diabetes Care1 month ago Treatment for CLL: Change Aplenty, More Coming  Medscape4 weeks ago
Pharma Letter

RESONATE STUDY: CLL/SLL Survival Improved with Ibrutinib

Volume 23 Issue Number 8 August 2014 ISSN 1059380 Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experience short response duration, who are 65 years or older or who have adverse cytogenetics (i.e., ...
 CancerWatch1 week ago 8/11/14 - IMBRUVICA® ibrutinib Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia CLL and CLL patients with del 17p  Pharmacy Choice2 weeks ago IMBRUVICA® ibrutinib Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia CLL and CLL patients with del 17p  HispanicBusiness.com3 weeks ago European Medicines Agency EMA Issues Positive Opinion, Recommends Full Approval of IMBRUVICA ibrutinib for Treatment of Two Blood Cancers  Pharmacy Choice3 weeks ago
[x]  

Drug hailed as breakthrough in leukaemia treatment

Ibrutinib was developed with the assistance of scientists at the Royal College of Surgeons in Ireland An international trial of a new drug for the treatment of the most common form of leukaemia has found it increases survival rates and leads to ...
 RTE Online2 months ago Clinical trials insight: oncology  pharmaphorum1 month ago Clinical trials prove new leukaemia drug boosts survival rate to 90%  Irish Medical Times2 months ago New leukaemia drug boosts survival rate to 90% and could eventually replace invasive chemical treatment  Health Canal2 months ago

Ibrutinib Results RESONATE in Refractory CLL

Bruce D. Cheson, MD: Hello. I am Bruce Cheson, Deputy Chief of Hematology/Oncology and Head of Hematology at Georgetown University Hospital and the Lombardi Comprehensive Cancer Center in Washington, DC. Welcome to this edition of Medscape Oncology ...
 General Medicine eJournal2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less